J B McGill
Affiliation: Washington University School of Medicine
- Clinical safety of the selective PKC-beta inhibitor, ruboxistaurinJanet B McGill
Washington University School of Medicine, 660 S Euclid, Campus Box 8127, St Louis, MO 63110, USA
Expert Opin Drug Saf 5:835-45. 2006..In controlled, randomised clinical trials, RBX had an adverse event profile comparable to placebo, and was well tolerated...
- Optimal use of beta-blockers in high-risk hypertension: a guide to dosing equivalenceJanet B McGill
Department of Medicine, Washington University School of Medicine, St Louis, Missouri 63110, USA
Vasc Health Risk Manag 6:363-72. 2010..beta-blockers with proven efficacy, once-daily dosing, and lower side effect profiles may become instrumental in the treatment of hypertensive diabetic and nondiabetic patients...
- Progress and controversies: treating obesity and insulin resistance in the context of hypertensionJanet B McGill
Washington University School of Medicine, Division of Endocrinology, Metabolism and Lipid Research, St Louis, MO 63110, USA
J Clin Hypertens (Greenwich) 11:36-41. 2009..Awareness of these pathophysiologic interrelations and their implications for treatment are likely to be of increasing importance for successful blood pressure management...
- Kidney Early Evaluation Program (KEEP). Findings from a community screening programJanet B McGill
Division of Endocrinology, Metabolism, and Lipid Research, Washington University, St Louis, MO, USA
Diabetes Educ 30:196-8, 200-2, 206. 2004..The Kidney Early Evaluation Program (KEEP), which was started in 1997, aims to identify persons at risk for chronic kidney disease (CKD) and encourage at-risk persons to seek evaluation and management from a healthcare provider...
- beta-blocker use and diabetes symptom score: results from the GEMINI studyJ B McGill
Department of Medicine, Washington University School of Medicine, St Louis, MO 63110, USA
Diabetes Obes Metab 9:408-17. 2007..In this paper, we report the results of a prespecified secondary analysis of GEMINI that sought to determine the effect of these two beta-blockers on commonly reported symptoms...
- Telmisartan plus hydrochlorothiazide versus telmisartan or hydrochlorothiazide monotherapy in patients with mild to moderate hypertension: a multicenter, randomized, double-blind, placebo-controlled, parallel-group trialJ B McGill
Department of Internal Medicine, Washington University School of Medicine, St Louis, Missouri 63110, USA
Clin Ther 23:833-50. 2001..Recent surveys reveal continuing deficiencies in the awareness, treatment, and control of hypertension. In many cases, failure to achieve blood pressure targets may be attributable to the use of antihypertensive monotherapy...
- Liraglutide: effects beyond glycaemic control in diabetes treatmentJ B McGill
Division of Endocrinology, Metabolism and Lipid Research, Washington University in St Louis, St Louis, MO 63110, USA
Int J Clin Pract Suppl 64:28-34. 2010..To review the non-glycaemic effects of liraglutide, including potential improvements in body weight, systolic blood pressure (SBP) and pancreatic beta-cell function...
- Combination treatment with telmisartan and hydrochlorothiazide in black patients with mild to moderate hypertensionJ B McGill
Department of Internal Medicine, Washington University School of Medicine, St. Louis, Missouri 63110, USA
Clin Cardiol 24:66-72. 2001..CONCLUSIONS: Telmisartan 80 mg combined with HCTZ 12.5 mg is effective and well tolerated in black patients with mild to moderate hypertension, providing greater antihypertensive activity than the corresponding monotherapies...
- Effects of nortriptyline on depression and glycemic control in diabetes: results of a double-blind, placebo-controlled trialP J Lustman
Department of Psychiatry, Washington University School of Medicine, St Louis, MO 63110, USA
Psychosom Med 59:241-50. 1997..This investigation evaluated the effects of nortriptyline on depression and glycemic control to see whether depression in diabetes is treatable and whether restoring mental health contributes to improved medical outcome...
- Effect of ruboxistaurin on urinary transforming growth factor-beta in patients with diabetic nephropathy and type 2 diabetesRichard E Gilbert
Department of Medicine, St Michael s Hospital, University of Toronto, Toronto, Ontario, Canada
Diabetes Care 30:995-6. 2007
- Efficacy of sertraline in prevention of depression recurrence in older versus younger adults with diabetesMonique M Williams
Department of Psychiatry, Washington University School of Medicine, St Louis, Missouri 63110, USA
Diabetes Care 30:801-6. 2007..A secondary analysis was performed to assess this effect in younger and older subsets of patients...
- Paradoxical increase in ventricular torsion and systolic torsion rate in type I diabetic patients under tight glycemic controlJina Chung
Cardiovascular Magnetic Resonance Laboratories, Washington University School of Medicine, St Louis, Missouri 63110, USA
J Am Coll Cardiol 47:384-90. 2006..This study sought to characterize the early features of diabetic cardiomyopathy by magnetic resonance imaging (MRI) tagging...
- Continued use of an integrated meter with electronic logbook maintains improvements in glycemic control beyond a randomized, controlled trialLori M B Laffel
Joslin Diabetes Center, Harvard Medical School, Boston, Massachusetts 02215, USA
Diabetes Technol Ther 9:254-64. 2007....
- Independent components of chronic kidney disease as a cardiovascular risk state: results from the Kidney Early Evaluation Program (KEEP)Peter A McCullough
Division of Cardiology, William Beaumont Hospital, Royal Oak, MI 48073, USA
Arch Intern Med 167:1122-9. 2007..We hypothesized that each of these chronic kidney disease-related measures would have an independent relationship with CVD...
- Body weight changes with beta-blocker use: results from GEMINIFranz H Messerli
St Luke s Roosevelt Hospital Center, New York City, NY 10019, USA
Am J Med 120:610-5. 2007....
- Protein kinase C beta inhibition: the promise for treatment of diabetic nephropathyPamela W Anderson
Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46234, USA
Curr Opin Nephrol Hypertens 16:397-402. 2007..Additional therapeutic agents are therefore urgently needed...
- Kidney outcomes in long-term studies of ruboxistaurin for diabetic eye diseaseKatherine R Tuttle
Providence Medical Research Center and University of Washington School of Medicine, Spokane, Washington, USA
Clin J Am Soc Nephrol 2:631-6. 2007..In contrast, in a trial of patients with diabetic retinopathy, investigators reported the adverse event "diabetic nephropathy" more frequently in patients who received RBX...
- Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathyMark E Williams
Harvard Medical School, Joslin Diabetes Center, Boston, MA 02215, USA
Am J Nephrol 27:605-14. 2007..We report the results of safety/tolerability studies in patients with overt nephropathy and type 1/type 2 diabetes treated with pyridoxamine, a broad inhibitor of advanced glycation...
- Lowering blood pressure with beta-blockers in combination with other renin-angiotensin system blockers in patients with hypertension and type 2 diabetes: results from the GEMINI TrialJackson T Wright
Department of Medicine, Case Western Reserve University, Cleveland, OH 44106, USA
J Clin Hypertens (Greenwich) 9:842-9. 2007..The use of carvedilol compared with metoprolol did not effect glycemic control...
- The decrease in microalbuminuria with carvedilol therapy is not enhanced by concurrent use of a statinDavid S H Bell
Endocr Pract 13:808-9. 2007
- Anemia and the role of erythropoietin in diabetesJanet B McGill
Washington University School of Medicine, St Louis, MO, USA
J Diabetes Complications 20:262-72. 2006..Promptly diagnosing and treating anemia in patients with diabetes may result in an improved quality of life and decreased morbidity and mortality...
- Alterations in left ventricular structure and function in type-1 diabetics: a focus on left atrial contribution to functionLinda R Peterson
Cardiovascular Division, Washington University School of Medicine, St Louis, MO 63110, USA
J Am Soc Echocardiogr 19:749-55. 2006....
- Sertraline for prevention of depression recurrence in diabetes mellitus: a randomized, double-blind, placebo-controlled trialPatrick J Lustman
Department of Veterans Affairs Medical Center, St Louis, MO, USA
Arch Gen Psychiatry 63:521-9. 2006..In patients with diabetes mellitus, depression is a prevalent and recurrent problem that adversely affects the medical prognosis...
- Depression and coronary heart disease in women with diabetesRay E Clouse
Department of Psychiatry, Washington University School of Medicine, St Louis, Missouri 63110, USA
Psychosom Med 65:376-83. 2003..Depression predicts onset of and poor outcome from CHD in nondiabetic populations. We hypothesized that the doubled rates of depression in female diabetic patients could help explain the high prevalence of CHD in women with diabetes...
- Lack of effect of sucralose on glucose homeostasis in subjects with type 2 diabetesV Lee Grotz
Medical and Nutritional Affairs, McNeil Nutritionals, New Bruswick, NJ 08903 2400, USA
J Am Diet Assoc 103:1607-12. 2003..To investigate the effect of 3-months' daily administration of high doses of sucralose, a non-nutritive sweetener, on glycemic control in subjects with type 2 diabetes...
- Circulating 1,5-anhydroglucitol levels in adult patients with diabetes reflect longitudinal changes of glycemia: a U.S. trial of the GlycoMark assayJanet B McGill
Washington University School of Medicine, St Louis, Missouri, USA
Diabetes Care 27:1859-65. 2004....
- Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trialGeorge L Bakris
Department of Preventive Medicine, Rush University Medical Center, Chicago, Ill, USA
JAMA 292:2227-36. 2004..Beta-blockers have been shown to decrease cardiovascular risk in patients with hypertension and type 2 diabetes mellitus (DM); however, some components of the metabolic syndrome are worsened by some beta-blockers...
- Rationale--Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): evolving the management of cardiovascular risk in patients with chronic kidney diseaseT Christian H Mix
Department of Development and Medical Affairs, Amgen Inc, Thousand Oaks, Calif, USA
Am Heart J 149:408-13. 2005....
- The effect of ruboxistaurin on nephropathy in type 2 diabetesKatherine R Tuttle
Research Department, The Heart Institute and Sacred Heart Medical Center, Spokane, WA 99204 2340, USA
Diabetes Care 28:2686-90. 2005..Ruboxistaurin selectively inhibits protein kinase C-beta and ameliorates kidney disease in animal models of diabetes. The purpose of this study was to evaluate the effects of ruboxistaurin on diabetic nephropathy in humans...
- Differential effects of beta-blockers on albuminuria in patients with type 2 diabetesGeorge L Bakris
Rush University Medical Center, Chicago, IL 60612, USA
Hypertension 46:1309-15. 2005..These differences cannot be explained by effects on blood pressure or alpha1-antagonism but may relate to antioxidant properties of carvedilol...
- Gastrointestinal absorption and plasma kinetics of soy Delta(5)-phytosterols and phytostanols in humansRichard E Ostlund
Division of Endocrinology, Diabetes and Metabolism, Washington University School of Medicine, Missouri 63017, USA
Am J Physiol Endocrinol Metab 282:E911-6. 2002..We conclude that the efficiency of phytosterol absorption is lower than what was reported previously and is critically dependent on the structure of both sterol nucleus and side chain...
- Fat-free foods supplemented with soy stanol-lecithin powder reduce cholesterol absorption and LDL cholesterolCurtis A Spilburg
Lifeline Technologies, Chesterfield, MO 63017, USA
J Am Diet Assoc 103:577-81. 2003..The objective of this work was to show that fat-free, lecithin-formulated soy stanols lower cholesterol absorption and serum LDL cholesterol...
- How to make exercise counseling more effective: lessons from rural AmericaKarrisa A Weidinger
Prevention Research Center and Department of Community Health, Saint Louis University School of Public Health, St Louis, MO USA
J Fam Pract 57:394-402. 2008..However, the prevalence and effectiveness of physician counseling is unknown in rural populations that are at increased risk for chronic diseases...
- Inpatient glycemic control on the vascular surgery serviceBrenda M Theilen
Department of Surgery, Washington University School of Medicine, St Louis, Missouri, USA
Endocr Pract 14:185-91. 2008..To describe a structured inpatient insulin management protocol and order set for glycemic control on a vascular surgery service...
- Effect of LDL cholesterol and treatment with losartan on end-stage renal disease in the RENAAL studyAndrew M Tershakovec
Merck Research Laboratories, Merck and Co, Inc, Upper Gwynedd, Pennsylvania, USA
Diabetes Care 31:445-7. 2008..LDL cholesterol lowering was associated with a lower risk of ESRD; however, this seemed to be largely an association with the reduction in albuminuria...
- The changing landscape of type 2 diabetes: the role of incretin-based therapies in managed care outcomesCurtis Triplitt
Texas Diabetes Institute, San Antonio, TX 78207, USA
J Manag Care Pharm 13:S2-16; quiz S17. 2007..Newer classes of antihyperglycemic agents, the incretin-based therapies, have the potential to improve goal achievement...
- Thiazolidinediones enhance insulin-mediated suppression of fatty acid flux in type 2 diabetes mellitusSusan B Racette
Department of Internal Medicine, Washington University School of Medicine, St Louis, MO 63110 1093, USA
Metabolism 51:169-74. 2002..However, TZD therapy did not affect whole-body glycerol R(a), possibly because of upregulation of lipoprotein lipase action on plasma triglycerides...
- How the diabetic eye loses visionJaime A Davidson
Division of Endocrinology, University of Texas, Southwestern Medical School, Dallas, Texas 75230, USA
Endocrine 32:107-16. 2007..Many experts and associations recommend that patients with diabetes have an yearly, thorough, dilated eye exam. This manuscript describes the case history of a patient with diabetes and vision loss...
- Serum 1,5-anhydroglucitol (GlycoMark ): a short-term glycemic markerJohn B Buse
Divisions of Endocrinology and of General Medicine and Clinical Epidemiology, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA
Diabetes Technol Ther 5:355-63. 2003..The behavior of this analyte is different from all others used in the management of diabetes, creating potential opportunities for its use in clinical practice...
- Continuous subcutaneous insulin infusion and multiple daily injection therapy are equally effective in type 2 diabetes: a randomized, parallel-group, 24-week studyPhilip Raskin
University of Texas, Southwestern Medical Center, Dallas, Texas 75390 8858, USA
Diabetes Care 26:2598-603. 2003..Compare the efficacy, safety, and patient satisfaction of continuous subcutaneous insulin infusion (CSII) therapy with multiple daily injection (MDI) therapy for patients with type 2 diabetes...
- Risk scores for predicting outcomes in patients with type 2 diabetes and nephropathy: the RENAAL studyWilliam F Keane
Merck and Co, Inc, Whitehouse Station, New Jersey, USA
Clin J Am Soc Nephrol 1:761-7. 2006..Future trials with a similar patient population and outcomes measures should consider adjusting analyses for baseline risk factors...
- Anxiety and poor glycemic control: a meta-analytic review of the literatureRyan J Anderson
Washington University School of Medicine, St Louis, Missouri 63110, USA
Int J Psychiatry Med 32:235-47. 2002..To determine whether anxiety is associated with poor glycemic control in adults with type 1 or type 2 diabetes...
- The effects of plasma insulin and glucose on myocardial blood flow in patients with type 1 diabetes mellitusMuthayyah Srinivasan
Cardiovascular Division, Department of Medicine, Washington University School of Medicine, St Louis, Missouri, USA
J Am Coll Cardiol 46:42-8. 2005..The objective of this study was to determine the impact of insulin and glucose on myocardial vasodilator function in patients with type 1 diabetes mellitus (T1DM)...
- Epidemiology of obesity and chronic kidney diseaseWill R Ross
Washington University School of Medicine, St Louis, MO 63110, USA
Adv Chronic Kidney Dis 13:325-35. 2006..Intervention strategies may need to target prenatal care through the elderly to combat this problematic epidemic...
- Increased myocardial fatty acid metabolism in patients with type 1 diabetes mellitusPilar Herrero
Division of Radiological Sciences, Edward Mallinckrodt Institute of Radiology, Washington University School of Medicine, St Louis, Missouri 63110, USA
J Am Coll Cardiol 47:598-604. 2006..The purpose of this study was to determine if myocardial fatty acid utilization (MFAU) and myocardial fatty acid oxidation (MFAO) are increased in diabetic patients...
- Psychosocial factors in patients with chronic kidney diseaseSteven D Weisbord
Adv Chronic Kidney Dis 14:316-8. 2007